1. Characterization, management, and risk factors of hyperglycemia during PI3K or AKT inhibitor treatment. (25th February 2022) Authors: Liu, Dazhi; Weintraub, Michael A.; Garcia, Christine; Goncalves, Marcus D.; Sisk, Ann Elizabeth; Casas, Alissa; Harding, James J.; Harnicar, Stephen; Drilon, Alexander; Jhaveri, Komal; Flory, James H. Journal: Cancer medicine Issue: Volume 11:Number 8(2022) Page Start: 1796 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Outpatient clinical pharmacy practice in the face of COVID-19 at a cancer center in New York City. (March 2021) Authors: Yerram, Prakirthi; Thackray, Jennifer; Modelevsky, Lisa R; Land, Josiah D; Reiss, Samantha N; Spatz, Krisoula H; Levoir, Andrea C; Pak, Terry K; Dao, Phuong H; Buege, Michael J; Derespiris, Lauren M; Lau, Carmen; Orozco, Jennifer S; Boparai, Manpreet; Koranteng, Lauren A; Reichert, Kate E; Yan, S... Journal: Journal of oncology pharmacy practice Issue: Volume 27:Number 2(2021) Page Start: 389 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Treatment of central venous catheter‐associated deep venous thrombosis in cancer patients with rivaroxaban. Issue 1 (22nd November 2016) Authors: Laube, Eva S.; Mantha, Simon; Samedy, Patrick; Wills, Jonathan; Harnicar, Stephen; Soff, Gerald A. Journal: American journal of hematology Issue: Volume 92:Issue 1(2017:Jan.) Page Start: E9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗